Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment initiation or switch to BIC/FTC/TAF - real-world safety and efficacy data from two HIV centers in Romania.
Săndulescu O, Irimia M, Benea OE, Mărdărescu M, Preoțescu LL, Dorobăț CM, Loghin II, Nicolau IC, Jipa RE, Popescu RȘ, Benea CL, Cozma A, Dărămuș IA, Miron VD, Prisăcariu LJ, Bahnă AF, Nistor I, Secrieru OM, George S, Bîrcă A, Dobrea L, Șogorescu AȘ, Viziteu I, Streinu-Cercel A. Săndulescu O, et al. Among authors: prisacariu lj. Germs. 2021 Dec 29;11(4):512-522. doi: 10.18683/germs.2021.1286. eCollection 2021 Dec. Germs. 2021. PMID: 35096668 Free PMC article.
Efficacy and safety of darunavir (Prezista(®)) with low-dose ritonavir and other antiretroviral medications in subtype F HIV-1 infected, treatment-experienced subjects in Romania: a post-authorization, open-label, one-cohort, non-interventional, prospective study.
Benea OE, Streinu-Cercel A, Dorobăţ C, Rugină S, Negruţiu L, Cupşa A, Duiculescu D, Chiriac C, Itu C, Prisăcariu LJ, Iosif I. Benea OE, et al. Among authors: prisacariu lj. Germs. 2014 Sep 1;4(3):59-69. doi: 10.11599/germs.2014.1057. eCollection 2014 Sep. Germs. 2014. PMID: 25276665 Free PMC article.
Proceedings of The 8th Romanian National HIV/AIDS Congress and The 3rd Central European HIV Forum : Sibiu, Romania. 5-7 May 2016.
Alexiev I, Dimitrova R, Gancheva A, Kostadinova A, Stoycheva M, Nikolova D, Elenkov I, Tilișcan C, Predescu M, Păunescu B, Streinu-Cercel A, Săndulescu O, Șchiopu CM, Hristache M, Brîndușe LA, Streinu-Cercel A, Todorovic M, Siljic M, Salemovic D, Nikolic V, Pesic-Pavlovic I, Ranin J, Jevtovic D, Stanojevic M, Tudor AM, Vlad D, Mărdărescu M, Petrea S, Petre C, Neagu-Drăghicenoiu R, Ungurianu R, Cibea A, Chirilă O, Anghelina C, Coserea I, Krikelli PA, Pavlitina E, Psichogiou M, Lamnisos D, Williams L, Korobchuk A, Skaathun B, Smyrnov P, Schneider J, Sypsa V, Paraskevis D, Hatzakis A, Friedman SR, Nikolopoulos GK, Dragović G, Srdić D, Khawla AM, Soldatović I, Nikolić J, Jevtović D, Nair D, Temereanca A, Rosca A, Ene L, Soontornniyomkij B, Diaconu C, Dita C, Achim C, Ruta S, Benea Ș, Moroti R, Jipa R, Manea E, Stan A, Benea E, Oțelea D, Hristea A, Hristea A, Lăpădat I, Jipa R, Moroti R, Benea Ș, Antonică D, Panait I, Petre R, Kowalska JD, Pietraszkiewicz E, Grycner E, Firlag-Burkacka E, Horban A, Vlaicu O, Bănică L, Paraschiv S, Tudor AM, Moroti R, Oțelea D, Dimitrijević B, Soldatović I, Jevtović Đ, Kusić J, Salemović D, Ranin J, Dragović G, Florea D, Bădicuț I, Rafila A, Camburu C, H… See abstract for full author list ➔ Alexiev I, et al. BMC Infect Dis. 2016 Jun 27;16 Suppl 3(Suppl 3):290. doi: 10.1186/s12879-016-1480-8. BMC Infect Dis. 2016. PMID: 27356504 Free PMC article.
Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials.
Nelson M, Amaya G, Clumeck N, Arns da Cunha C, Jayaweera D, Junod P, Li T, Tebas P, Stevens M, Buelens A, Vanveggel S, Boven K; ECHO and THRIVE Study Groups. Nelson M, et al. J Antimicrob Chemother. 2012 Aug;67(8):2020-8. doi: 10.1093/jac/dks130. Epub 2012 Apr 24. J Antimicrob Chemother. 2012. PMID: 22532465 Free PMC article. Clinical Trial.
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials.
Orkin C, Molina JM, Cahn P, Lombaard J, Supparatpinyo K, Kumar S, Campbell H, Wan H, Teal V, Jin Xu Z, Asante-Appiah E, Sklar P, Teppler H, Lahoulou R; DRIVE-FORWARD and DRIVE-AHEAD collaborators. Orkin C, et al. Lancet HIV. 2024 Feb;11(2):e75-e85. doi: 10.1016/S2352-3018(23)00258-8. Epub 2023 Dec 20. Lancet HIV. 2024. PMID: 38141637 Clinical Trial.
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, Lai MT, Rodgers A, Lupinacci L, Kumar S, Sklar P, Hanna GJ, Hwang C, Martin EA; DRIVE-FORWARD trial group. Molina JM, et al. Lancet HIV. 2020 Jan;7(1):e16-e26. doi: 10.1016/S2352-3018(19)30336-4. Epub 2019 Nov 15. Lancet HIV. 2020. PMID: 31740348 Clinical Trial.
13 results